Rectal Cancer: Predictive Biomarkers and Treatment Strategies
Author Information
Author(s): Martins Sheila, Veiga Pedro, Tralhão José Guilherme, Carreira Isabel Marques, Ribeiro Ilda Patrícia
Primary Institution: Portuguese Oncology Institute of Coimbra
Hypothesis
Can molecular biomarkers predict the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy?
Conclusion
Identifying molecular biomarkers may significantly improve treatment strategies for rectal cancer by predicting patient responses to therapy.
Supporting Evidence
- Approximately 20% of rectal cancers completely disappear after chemoradiotherapy.
- Some biomarkers like CIN are associated with a good response to treatment.
- TP53 and KRAS mutations are linked to poorer treatment responses.
- Liquid biopsies may play a significant role in evaluating treatment effectiveness in the future.
Takeaway
This study looks for special markers in rectal cancer that can help doctors know how well a treatment will work, so they can choose the best plan for each patient.
Methodology
The review analyzes various molecular pathways and biomarkers related to rectal cancer and their potential predictive value for treatment response.
Limitations
The study highlights the need for larger, multicenter studies to validate findings due to variability in results across different studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website